Question

Question 50 What is the emetogenic risk for a patient who is being treated with rituximab, cyclophosphamide, daxorubicin, vincristine, and predrisone? Oa Moderate O b Low O c Minimal Od High Question 51 A patient is scheduled to receive melphalan 140 mg/m2. The patienc's measurements are as folows: h the dose to be administeredt eight 173 cm and weight 85 ig What is e b 283 mg O 295 mg Od 280 mg Question 52 Which immunotherapy agent is approved for the treatment of sarcomas? Question 53 Sterectactic radiourgery performed after the subrotal resection of a malignant meningoma is an example of which type of therapy O b Neoadjuvant Question 54 To ensure chat the hospital proviced gloves are approprate for administering chemother py the nurse O a reads safety information on the outside of the box O b reviews the insttutien's medication U refers to the policy and procedure manual Od verifies ARC manfacturers classfication ast. handboek Question 55 A partient who is being discharged with an order for oral methetresate should be instructied to do which of the following

Answer 1

50) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone are chemotherapeutic drugs. And this causes emetogenesis. these are moderately emetogenic drugs

51) melphalan

dose- 140mg/m²

BSA of patient = root of ( height in cm * weight in kg )/ 3600

=2.021069

required dose =dose * BSA

=140 * 2.021069

=282.9497

i.e,= 283 mg

52) olaratumab is used as immunotherapy agent for the treatment of sarcomas. because it is an antibody which blocks the biochemical pathway that boosts the growth of sarcoma cells.

53) adjuvant therapy

it refers to a treatment method in cancer  inorder to reduce the recurrance of cancer surgery is followed by chemo or radiotherapy

54)inorder to ensure the hospital provided gloves are appropriate for administering chemotherapy the nurse has to verifies IARC manufactureres clasification list and also need to read safety information on the outside of box